Scilex (SCLX) Projected to Post Earnings on Wednesday

Scilex (NASDAQ:SCLX) is projected to announce its Q2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($0.1813) per share and revenue of $16.00 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 7:00 AM ET.

Scilex (NASDAQ:SCLX) last posted its quarterly earnings data on Friday, August 14th. The company reported ($16.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($16.47). The company had revenue of $7.64 million during the quarter, compared to the consensus estimate of $16.00 million.

Scilex Price Performance

NASDAQ SCLX opened at $5.43 on Monday. The business has a 50 day simple moving average of $7.20 and a 200 day simple moving average of $7.40. The stock has a market capitalization of $46.12 million, a P/E ratio of -0.11 and a beta of 1.67. Scilex has a one year low of $4.20 and a one year high of $34.27.

Analyst Ratings Changes

Several brokerages have weighed in on SCLX. Weiss Ratings restated a “sell (e+)” rating on shares of Scilex in a research note on Tuesday, June 16th. Wall Street Zen cut Scilex from a “sell” rating to a “strong sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Scilex

Several hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC grew its holdings in shares of Scilex by 622.2% during the 4th quarter. Armistice Capital LLC now owns 476,674 shares of the company’s stock worth $5,815,000 after acquiring an additional 410,674 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Scilex by 31.2% in the first quarter. Goldman Sachs Group Inc. now owns 136,352 shares of the company’s stock worth $34,000 after acquiring an additional 32,449 shares during the last quarter. Renaissance Technologies LLC increased its stake in Scilex by 100.7% during the 4th quarter. Renaissance Technologies LLC now owns 38,464 shares of the company’s stock valued at $469,000 after purchasing an additional 19,300 shares in the last quarter. 683 Capital Management LLC bought a new stake in shares of Scilex during the fourth quarter valued at approximately $333,000. Finally, XTX Topco Ltd bought a new stake in shares of Scilex in the 4th quarter worth $249,000. 69.67% of the stock is owned by institutional investors.

About Scilex

Scilex Holdings, Inc (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways.